Background: A meta-analysis was conducted to assess the impact of postoperative radiotherapy (PORT) in renal cell carcinoma (RCC) on overall survival (OS), disease-free survival (DFS) and locoregional failure (LRF).
introduction
The incidence of renal cell carcinoma (RCC) over the last 20 years has progressively increased accounting for 3% of cancers and 2% of all cancer-related deaths [1, 2] . Further, due to the widespread use of modern imaging, incidental renal tumors have emerged as a new clinical entity [3] . For localized RCC, radical nephrectomy with or without lymph node (LN) resection is the treatment of choice. Even if a tumor has been removed totally, the chance of locoregional failure (LRF) remains, especially in high-risk patients with perinephric fat extension, involved margins and gross residual disease [4] . To minimize the risks of LRF, the effectiveness of postoperative radiotherapy (PORT) to renal bed and draining LNs has not been widely accepted. Some of the retrospective studies have shown encouraging results for improved survival and locoregional control [5] [6] [7] . However, prospective trials have failed to demonstrate any benefit of PORT after radical nephrectomy [8, 9] . The possible explanation for lack of benefit from PORT in these prospective trials may be poor patient selection and the time period during which these studies were conducted utilizing conventional older methods of radiotherapy.
According to Aref et al. [10] , higher incidence of distant metastasis and the paucity of local failure might explain the failure of PORT to improve survival results in these trials. Further, if benefit from PORT exists if it would be demonstrable only in patients with high-risk features that would increase their risk of local failure. Recent guidelines have also abandoned the routine use of PORT in patients with positive margins and LNs.
Thus, to clarify these controversial issues, we conducted a metaanalysis that assessed whether PORT led to better outcomes than did nephrectomy alone in localized RCC. We also attempted to review the radiotherapy techniques utilized, field sizes, radiation dose and late gastrointestinal (GI) and hepatic side-effects.
materials and methods

studies and study population
The search criteria were that studies had to be either complete articles of randomized controlled trials or retrospective if these were well controlled. The abstracts from which full details were available were also included. The Medline, CANCERLIT and Cochrane library databases were searched using the terms 'renal or kidney', 'cancer, carcinoma or hypernephroma', 'radiotherapy, radiation' and 'adjuvant or postoperative'. These terms were then combined for to search for randomized controlled review and metaanalysis. The relevant articles were selected by two methodologists. Then, only studies were included which met the criteria. The patients had to have histologically confirmed localized RCC and to have undergone radical nephrectomy and PORT. The studies that included patients with metastatic disease were excluded.
outcome measures
The outcome measures were overall survival (OS), disease-free survival (DFS), locoregional control and GI and hepatic late toxicity.
review analysis
The all analyses were carried out on an intention-to-treat analysis basis. For the categorical variables, weighted risk ratios and their 95% confidence intervals (CIs) were calculated using comprehensive meta-analysis software. The results were tested for heterogeneity at the significant level of P <0.05. If there was evidence of heterogeneity, a random effects model was used for meta-analysis; otherwise, fixed effects model was used. The odds ratio and 99% CI were calculated for each trial and presented in forest plot.
We determined the OS, DFS and LRF on the basis of the follow-up period mentioned in each trial. We also determined the percentage of patients that suffered a late GI and hepatic grade 2 or more morbidity.
Publication bias was evaluated using the funnel graph, the BeggMazumdar-adjusted rank correlation test [11] and the Egger test [12] . For heterogeneity, we carried out the Cochran's Q test to determine whether the studies are homogenous. All analysis was carried out using comprehensive meta-analysis software. The electronic search revealed 3048 relevant citations. After screening 20, full-text articles were retrieved for further assessment. Finally, seven studies were identified that met the criteria ( Figure 1) ; the total population of these studies was 735 patients. Details are given in Table 1 .
locoregional failure
All seven studies with a population of 735 patients analyzed the locoregional control as one of the outcomes. The LRF were significantly low in patients with PORT (P £ 0.0001). The pooled odds ratio was 0.47 (99% CI 0.33-0.68). The result of the test for heterogeneity was not statistically significant (P = 0.14). The overall benefit from PORT to control LRF is shown in Figure 2 .
disease-free survival
All seven studies with 735 patients examined the DFS as a one of the outcomes. The overall DFS was not increased in PORT arm (P = 0.14) without any heterogeneity. Overall odds ratios did not show any differences between PORT and nephrectomyalone arms (Figure 3 ).
overall survival
All the mentioned studies, with 735 patients, addressed the OS as one of the outcomes. One study showed improved OS, five no difference and one study better survival in nephrectomyalone arms. The pooled odds ratios were not statistically different between PORT and nephrectomy arms without any heterogeneity (Figure 4 ).
PORT-related GI and hepatic side-effects
In all studies, six treatment-related deaths were seen. Four patients in the PORT arm died of severe GI toxicity and two patients died of hepatic failure. But overall side-effects in PORT were manageable without any significant difference (Table 2 ). In six trials, patients were treated with parallel-opposed fields, i.e. anteroposterior/posteroanterior, and in one study, more than two fields were used. Mean field sizes used were 15 · 15 cm 2 to include renal bed and draining LNs ( Figure 5 ). Computed tomography-based planning was done only in six patients. The majority of patients was treated on Cobalt 60 and non-multileaf collimators linear accelerators. The mean dose prescribed was 48.22 Gy (24 Gy-63 Gy). In all patients after 45 Gy, field sizes were reduced.
publication bias
The funnel plot revealed the broad-shaped funnel (Figure 6) , showing no significant publication bias (P values from BeggMazumdar test and Egger test were 0.27 and 0.14, respectively). The broad shape may be attributed to less number of pooled patients.
discussion
PORT has remained controversial in the literature so far; recent guidelines have completely ignored the use of PORT following radical nephrectomy even in patients with residual microscopic disease on the basis of data from trials in the 1970s and 1980s. The older radiotherapy techniques, poor case selection, improper dose and fractionation, and nonavailability of modern imaging to detect locoregional recurrences were reasons to solve the old question of PORT in RCC by this meta-analysis. The basic purpose of this meta-analysis was to obtain a large enough sample from different studies to reveal a possible significant difference between nephrectomy alone and nephrectomy followed by PORT in terms of locoregional control, DFS and OS. In this meta-analysis, we selected all well-controlled retrospective and randomized controlled cohort studies published till date. The pooled analysis favored PORT regarding locoregional control but there was no impact on OS and DFS. 
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In the study by Ulutin et al. [13] , further analysis showed that the benefit of PORT was seen only in patients with T3 and N2 (more than one regional LN involved). In this study, distant metastases were seen at 50% and 79% in PORT and nephrectomy-alone arms, respectively, favoring to PORT.
In the National Cancer Institute Cairo study, no significant difference in locoregional control was seen between PORT and nephrectomy-alone arms because PORT arm had more highrisk patients (renal vein invasion, capsular infiltration). Both renal vein invasion and capsular infiltration are considered the poor prognostic factors [18, 19] .
Makarewicz et al. [15] showed delayed time to progression to local and distant metastasis in PORT arm especially in patients with T3 stage.
Contrary to retrospective studies, the prospective clinical trials failed to show any benefit of PORT. Both the randomized controlled trials by the Copenhagen Renal Cell Carcinoma Study Group [9] and Finney [8] showed higher GI and hepatic sequelae and mortality in the PORT arm. Interestingly, these trials used higher daily radiation doses (>2 Gy) and larger treatment fields. The use of hypofractionated radiotherapy is still is not widely accepted for various tumors, unless computed-based treatment planning systems and dose-volume histogram data are incorporated [20] [21] [22] . Even if low a/b were estimated for renal cancer on the basis of linear quadratic models [23] , care was required for small-bowel and liver tolerance, and its volume in radiation fields to prevent radiation-induced liver disease and enteropathy.
In our meta-analysis, apart from these trials, remaining studies and two single-arm studies [24, 25] showed improved locoregional control following PORT.
Other possible critic may be the lower locoregional occurrences, as few data have indicated local recurrence from 2% to 14% [26, 27] . However, in our meta-analysis, the LRF as initial presentation was seen from 4% to 19.7% (Table 3) . The local recurrences are associated with poor survival outcome because most of them are not completely resectable [28] . We also believe that incidence and OS of RCC is increasing with modern imaging and advent of targeted therapy [29, 30] and in the next decade, we are going to see more locoregional recurrences. In conclusion, our meta-analysis showed PORT definitely reduces locoregional recurrences and with acceptable GI toxicity if modern techniques (three dimensional conformal radiation and intensity-modulated radiotherapy) are utilized for high-risk patients (T3, capsule infiltration, renal vein). There is a need to run a multi-institutional trial to see additional benefits of PORT regarding DFS and OS along with targeted therapy, not simply believing no impact of PORT on the basis of past negative cohort studies. Figure 7 shows a proposal for a multicenter, randomized, controlled trial including sample size, eligibility criteria and treatment techniques. original article Annals of Oncology
